WO2006056293A1 - Oral composition for enhancing skin properties - Google Patents

Oral composition for enhancing skin properties Download PDF

Info

Publication number
WO2006056293A1
WO2006056293A1 PCT/EP2005/011658 EP2005011658W WO2006056293A1 WO 2006056293 A1 WO2006056293 A1 WO 2006056293A1 EP 2005011658 W EP2005011658 W EP 2005011658W WO 2006056293 A1 WO2006056293 A1 WO 2006056293A1
Authority
WO
WIPO (PCT)
Prior art keywords
oil
product according
product
skin
emulsifier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2005/011658
Other languages
French (fr)
Inventor
John Casey
Gail Jenkins
Julia Sarah Rogers
Simon David Wantling
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hindustan Unilever Ltd
Unilever NV
Original Assignee
Hindustan Lever Ltd
Unilever NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hindustan Lever Ltd, Unilever NV filed Critical Hindustan Lever Ltd
Priority to DE602005019207T priority Critical patent/DE602005019207D1/en
Priority to AT05800022T priority patent/ATE456373T1/en
Priority to EP05800022A priority patent/EP1833498B1/en
Priority to PL05800022T priority patent/PL1833498T3/en
Priority to US11/791,783 priority patent/US20080200546A1/en
Publication of WO2006056293A1 publication Critical patent/WO2006056293A1/en
Anticipated expiration legal-status Critical
Priority to US12/640,124 priority patent/US20100093844A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A23L33/155—Vitamins A or D
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to a consumable product for enhancing skin appearance.
  • Dietary fish oil is known to convey significant protection against UVR-induced erythema upon ingestion.
  • Carotenoids such as lycopene and ⁇ -carotene have also been shown to give significant protection against UVR-induced erythema when induced orally.
  • ⁇ -3 polyunsaturated fatty acids are believed to be more effective than ⁇ - ⁇ PUFA' s at delivering a skin benefit. Oral consumption of W-3 PUFA's leads to a reduction in UV-induced erythema and in the levels of key inflammatory mediators, such as Prostaglandin E2 in the skin, ⁇ - ⁇ PUFA's do not exhibit the same functionality.
  • Fish oil is a convenient source of ⁇ -3 because it is available in large quantities at a reasonable cost. However, it has the major disadvantage of being oily and being prone to oxidative degredation (i.e. going rancid) .
  • US 6,589,535 discloses a nutritional supplement which contains an oil rich in ⁇ -3 and ⁇ - ⁇ fatty acids and a carotenoid in combination to combat the harmful effects of xenobiotics on the skin, in particular on the skin's immune system.
  • this is limited to food supplements such as capsules or tablets and does not disclose how such materials may be delivered via a beverage or other food product.
  • Blackcurrent seed oil is preferred as the source of the fatty acids, however this contains the less utility ⁇ -3 PUFA ⁇ -linolenic acid and is not as rich overall in ⁇ -3 PUFA's as fish oil.
  • US2003/0082275 discloses a drinkable ⁇ -3 preparation, which is storage stable.
  • the drink disclosed contains a very high level of oil and consequently is unstable, forming a two-phase beverage upon storage.
  • a drink having 4wt% oil, giving an ⁇ -3 concentration of 1.6 wt% is exemplified.
  • Egg yolk is used as an emulsifier which contains approximately 8wt% lecithin.
  • Other beverages have recently appeared on the market but which have substantially less quantities of fish oil.
  • One in particular contains lecithin and 0.04 wt% fish oil.
  • a water-based product comprising a high quantity of ⁇ -3 oil, and antioxidant, a flavouring and a phospholipid emulsifier provides a product which can be consumed regularly and frequently, is good tasting and delivers noticeable skin benefits over time.
  • the present invention provides a product suitable for regular consumption, comprising at least 50% water, 0.2 to 5 wt% of an oil comprising at least 12wt% of docosahexaenoic acid and eicosapentaenoic acid, an antioxidant, a flavouring and at least 0.01 wt% food-grade phospholipid emulsifier.
  • the product is water based, i.e. comprises at least 50wt% water, preferably at least 60wt% or even at least 70wt% water. It may be either liquid or frozen.
  • the product thus has the sensation of being a regular water-based product and thus be consumed on a regular basis as part of a consumers normal diet. For example it could replace a fruit juice normally consumed at breakfast time.
  • the product has a viscosity of from 2 to 100 centipoise at a shear rate of Is and at 25°C.
  • Oil Fish oil is known to be rich in ⁇ -3 polyunsaturated fatty acids.
  • the present inventors have also confirmed sporadic reports that ⁇ -3 polyunsaturated fatty acids can give noticeable skin benefits when consumed in high enough quantities.
  • the product of the present invention comprises from 0.2 to 5 wt% of oil.
  • the product comprises from 0.4 to 3 wt% oil.
  • the oil is made up of at least 12 wt% of DHA and EPA.
  • it is made up of at least 20 wt% EPA and DHA, more preferably at least 30 wt% EPA and DHA.
  • Eicosapentaenoic acid is one of several ⁇ -3 fatty acids used by the body. Increased intake of EPA has been shown to be beneficial in coronary heart disease, high blood pressure, and inflammatory disorders such as rheumatoid arthritis.
  • DHA is an ⁇ -3, polyunsaturated, 22-carbon fatty acid. It is also present in abundance in certain fish (such as tuna and bluefish) and marine animal oils.
  • Eicosapentaenoic acid and docosahexaenoic acid (DHA) , come from cold water fish such as wild salmon (not farm raised) , mackerel, sardines, herring and other northern marine animals. Fish can make EPA and DHA from the ⁇ 3 essential fatty acid, alpha-linolenic acid (LNA) , but get much of their EPA and DHA D
  • LNA alpha-linolenic acid
  • brown and red algae have begun to be grown commercially for EPA and DHA. These make 10 to 14% of long-chain ⁇ 3s (on dry weight basis) and can be used as food sources of EPA and DHA-containing triglycerides.
  • Antioxidant is required in order to prevent or slow down the natural oxidative degradation of the fish oil.
  • Rancid fish oil not only has an unpleasant taste but may even have negative health effects (Kubow S., "Toxicity of dietary lipid peroxidation products", Trends in Food Sciences & Technology, September, 67-71 (1990) ) .
  • Suitable antioxidants can be selected, although not exclusively from the following list, either singularly or in combination: TBHQ, Ascorbyl esters (e.g. ascorbyl palmitate) , ascorbic acid, Tocopherols, Rosemary Extract, fruit concentrates or extracts, black or green tea extract, Propyl Gallate, essential oils or oleoresins, butylated hydroxyanisole (BHA) , butylated hydroxytoluene (BHT) , citric acid or esters, co enzyme QlO, Tocotrienols, Chelators (e.g. EDTA), Carriers, polyphenols, phenolic compounds, flavonoids, oxygen scavengers.
  • Especially preferred antioxidants are vitamins C and E. Not only are these effective antioxidants but they also have been shown to give skin benefits when consumed.
  • an amount of antioxidant should be added sufficient to prevent the fish oil from going rancid over a typical shelf-life of 6 months.
  • the amount of antioxidant will depend on the type and activity of the antioxidant used.
  • the product has a ratio of antioxidant to oil of from 1:10 to 1:100 based on the antioxidant activity of vitamin C. E.g., if an antioxidant with twice the activity of vitamin C was used, the ratio would be from 1:20 to 1:200.
  • an antioxidant activity is as measured using an appropriate assay (e.g. Trolox equivalent antioxidant capacity) .
  • the flavouring may be natural or synthetic. It is required to make the product more palatable for consumption.
  • the inventors have found that not all food-grade emulsifiers are suitable for carrying high quantities of fish oil. However, surprisingly, phospholipid emulsifiers were found to be very suitable.
  • a food grade phospholipid emulsifier is required in order to carry the fish oil in the oil-in-water emulsion. It is preferred that the phospholipid emulsifier is lecithin. Phospholipid emulsifiers are oil soluble, but the lecithin can be added to either phase prior to emulsification. Preferably it is added to the aqueous phase.
  • the inventors have found that it is required that there be at least 0.01 wt% food-grade phospholipid emulsifier. Preferably from 0.05 to 3 wt%, more preferably from 0.1 to 1 wt%. Further additional ingredients
  • the product also comprises from 0.01 to 0.5 wt% soy isoflavones. This is equivalent to from 10 to 500 mg/100g.
  • the product contains from 0.01 to 0.3 wt% soy isoflavones.
  • Soy isoflavones are components within soy that have a biological function similar to oestrogen, including the promotion of dermal matrix protein synthesis. In addition, they have also been shown to have anti-inflammatory properties and stimulate synthesis of hyaluronic acid - a proteoglycan in skin which can retain water and thereby influence skin firmness.
  • the soy isoflavones are selected from genistein and daidzein.
  • the product also comprises from 0.0005 to 0.1 wt% carotenoids. This is equivalent to from 0.5 to 100 mg/lOOg.
  • the product contains from 0.002 to 0.04 wt% carotenoids.
  • the carotenoids being oil soluble, would be comprised predominantly within the oil phase.
  • Highly preferred carotenoids are ⁇ -carotene, and lycopene. These carotenoids provide moderate protection from UV induced erythema, thought to be due to their antioxidant functionality including scavenging of reactive oxygen species.
  • the product of the present invention is made up by preparing an aqueous phase and an oil phase.
  • the water-soluble ingredients are put together in the aqueous phase and the oil- soluble ingredients in the oil phase.
  • the exception is the emulsifier. It has been surprisingly found that the emulsifier, which is oil-soluble, gives a more stable emulsion when it is added to the aqueous phase.
  • the two phases are then blended together in conventional emulsifier equipment.
  • the produced emulsion is shelf-stable and the oil does not go rancid for months.
  • the oil phase and aqueous phase are then blended together to ' form a homogenous stable emulsion.
  • the oil is on a powdered carrier material to assist emulsion formation.
  • the stable emulsion may then be packaged in a sealed container such as a metal, coated cardboard (e.g. tetra Pak) or plastic container.
  • a sealed container such as a metal, coated cardboard (e.g. tetra Pak) or plastic container.
  • the container is then preferably sealed so as to give no headspace or a gas filled (e.g. nitrogen or carbon dioxide) headspace. This assists still further in preventing the fish oil oxidising.
  • the emulsion may be frozen and packaged and sold as a frozen consumer product.
  • a beverage was made up with the following formula:
  • the beverage had a good taste and colour, and 150ml twice per day for a few weeks gave noticeable improvements in the appearance and texture of the skin.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Health & Medical Sciences (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Botany (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Edible Oils And Fats (AREA)
  • Non-Alcoholic Beverages (AREA)
  • Cosmetics (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Dairy Products (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A stable consumable emulsion, comprising at least 50% water, 0.2 to 3 wt% of an oil comprising at least 12wt% of docosahexaenoic acid and eicosapentaenoic acid, an antioxidant, a flavouring and at least 0.01 wt% food-grade phospholipid emulsifier is provided which provides noticeable improvements in skin when consumed regularly.

Description

ORAL COMPOSITION FOR ENHANCING SKIN PROPERTIES
The present invention relates to a consumable product for enhancing skin appearance.
BACKGROUND AND PRIOR ART
Improving the appearance and feel of human skin has received a great deal of research effort. However, the vast majority of commercially available product address this problem by acting on the exterior of the skin. The most common form being a topical skin cream. However, such topical application have their limitations and deal primarily with the dead surface layers of the skin. It is known that certain ingredients can provide improvements in skin appearance and texture from being ingested. Such ingredients thus act from the interior of the skin and therefore can provide greater opportunities for improving the skin by accessing the living interior. Furthermore such an effect may be perceived by the general public as being more potent or medical in nature than a topical application.
Dietary fish oil is known to convey significant protection against UVR-induced erythema upon ingestion.
Carotenoids such as lycopene and β-carotene have also been shown to give significant protection against UVR-induced erythema when induced orally.
Likewise, vitamins E & C when taken orally in combination have also been shown to provide protection against ϋVR-induced erythema. ω-3 polyunsaturated fatty acids (PUFA' s) are believed to be more effective than ω-β PUFA' s at delivering a skin benefit. Oral consumption of W-3 PUFA's leads to a reduction in UV-induced erythema and in the levels of key inflammatory mediators, such as Prostaglandin E2 in the skin, ω-β PUFA's do not exhibit the same functionality. Fish oil is a convenient source of ω-3 because it is available in large quantities at a reasonable cost. However, it has the major disadvantage of being oily and being prone to oxidative degredation (i.e. going rancid) .
US 6,589,535 (Johnson & Johnson) discloses a nutritional supplement which contains an oil rich in ω-3 and ω-β fatty acids and a carotenoid in combination to combat the harmful effects of xenobiotics on the skin, in particular on the skin's immune system. However, this is limited to food supplements such as capsules or tablets and does not disclose how such materials may be delivered via a beverage or other food product. Blackcurrent seed oil is preferred as the source of the fatty acids, however this contains the less efficaceous ω-3 PUFA α-linolenic acid and is not as rich overall in ω-3 PUFA's as fish oil.
However a problem with food supplements is that they are not very palatable and can be perceived as being medicinal and are therefore less likely to be consumed regularly.
US2003/0082275 discloses a drinkable ω-3 preparation, which is storage stable. The drink disclosed contains a very high level of oil and consequently is unstable, forming a two-phase beverage upon storage. A drink having 4wt% oil, giving an ω-3 concentration of 1.6 wt% is exemplified. Egg yolk is used as an emulsifier which contains approximately 8wt% lecithin. Other beverages have recently appeared on the market but which have substantially less quantities of fish oil. One in particular contains lecithin and 0.04 wt% fish oil.
The present inventors have discovered that a water-based product comprising a high quantity of ω-3 oil, and antioxidant, a flavouring and a phospholipid emulsifier provides a product which can be consumed regularly and frequently, is good tasting and delivers noticeable skin benefits over time.
Thus, the present invention provides a product suitable for regular consumption, comprising at least 50% water, 0.2 to 5 wt% of an oil comprising at least 12wt% of docosahexaenoic acid and eicosapentaenoic acid, an antioxidant, a flavouring and at least 0.01 wt% food-grade phospholipid emulsifier.
DETAILED DESCRIPTION OF THE INVENTION
The product
The product is water based, i.e. comprises at least 50wt% water, preferably at least 60wt% or even at least 70wt% water. It may be either liquid or frozen. The product thus has the sensation of being a regular water-based product and thus be consumed on a regular basis as part of a consumers normal diet. For example it could replace a fruit juice normally consumed at breakfast time.
Preferably the product has a viscosity of from 2 to 100 centipoise at a shear rate of Is and at 25°C.
Oil Fish oil is known to be rich in ω-3 polyunsaturated fatty acids. The present inventors have also confirmed sporadic reports that ω-3 polyunsaturated fatty acids can give noticeable skin benefits when consumed in high enough quantities. Unfortunately the commercially available drinks on the market contain at least an order of magnitude less than the amount where any beneficial effect becomes noticeable.
The product of the present invention comprises from 0.2 to 5 wt% of oil. Preferably the product comprises from 0.4 to 3 wt% oil. The oil is made up of at least 12 wt% of DHA and EPA. Preferably it is made up of at least 20 wt% EPA and DHA, more preferably at least 30 wt% EPA and DHA. These levels ensure that the consumable emulsion remains stable and yet also permit noticeable benefits from the fish oil to be observed when consumed regularly.
Eicosapentaenoic acid (EPA) is one of several ω-3 fatty acids used by the body. Increased intake of EPA has been shown to be beneficial in coronary heart disease, high blood pressure, and inflammatory disorders such as rheumatoid arthritis.
DHA is an ω-3, polyunsaturated, 22-carbon fatty acid. It is also present in abundance in certain fish (such as tuna and bluefish) and marine animal oils.
Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) , come from cold water fish such as wild salmon (not farm raised) , mackerel, sardines, herring and other northern marine animals. Fish can make EPA and DHA from the ω3 essential fatty acid, alpha-linolenic acid (LNA) , but get much of their EPA and DHA D
from brown and red algae which manufacture EPA and DHA from carbohydrates - sugar, starch, cellulose, etc.
More recently, brown and red algae have begun to be grown commercially for EPA and DHA. These make 10 to 14% of long-chain ω3s (on dry weight basis) and can be used as food sources of EPA and DHA-containing triglycerides.
Antioxidant
Antioxidant is required in order to prevent or slow down the natural oxidative degradation of the fish oil. Rancid fish oil not only has an unpleasant taste but may even have negative health effects (Kubow S., "Toxicity of dietary lipid peroxidation products", Trends in Food Sciences & Technology, September, 67-71 (1990) ) .
Suitable antioxidants can be selected, although not exclusively from the following list, either singularly or in combination: TBHQ, Ascorbyl esters (e.g. ascorbyl palmitate) , ascorbic acid, Tocopherols, Rosemary Extract, fruit concentrates or extracts, black or green tea extract, Propyl Gallate, essential oils or oleoresins, butylated hydroxyanisole (BHA) , butylated hydroxytoluene (BHT) , citric acid or esters, co enzyme QlO, Tocotrienols, Chelators (e.g. EDTA), Carriers, polyphenols, phenolic compounds, flavonoids, oxygen scavengers.
Especially preferred antioxidants are vitamins C and E. Not only are these effective antioxidants but they also have been shown to give skin benefits when consumed.
An amount of antioxidant should be added sufficient to prevent the fish oil from going rancid over a typical shelf-life of 6 months. Clearly the amount of antioxidant will depend on the type and activity of the antioxidant used. However, preferably the product has a ratio of antioxidant to oil of from 1:10 to 1:100 based on the antioxidant activity of vitamin C. E.g., if an antioxidant with twice the activity of vitamin C was used, the ratio would be from 1:20 to 1:200.
For these purposes an antioxidant activity is as measured using an appropriate assay (e.g. Trolox equivalent antioxidant capacity) .
Flavouring
The flavouring may be natural or synthetic. It is required to make the product more palatable for consumption.
Emulsifier
The inventors have found that not all food-grade emulsifiers are suitable for carrying high quantities of fish oil. However, surprisingly, phospholipid emulsifiers were found to be very suitable.
A food grade phospholipid emulsifier is required in order to carry the fish oil in the oil-in-water emulsion. It is preferred that the phospholipid emulsifier is lecithin. Phospholipid emulsifiers are oil soluble, but the lecithin can be added to either phase prior to emulsification. Preferably it is added to the aqueous phase.
The inventors have found that it is required that there be at least 0.01 wt% food-grade phospholipid emulsifier. Preferably from 0.05 to 3 wt%, more preferably from 0.1 to 1 wt%. Further additional ingredients
It is preferred that the product also comprises from 0.01 to 0.5 wt% soy isoflavones. This is equivalent to from 10 to 500 mg/100g. Preferably the product contains from 0.01 to 0.3 wt% soy isoflavones. Soy isoflavones are components within soy that have a biological function similar to oestrogen, including the promotion of dermal matrix protein synthesis. In addition, they have also been shown to have anti-inflammatory properties and stimulate synthesis of hyaluronic acid - a proteoglycan in skin which can retain water and thereby influence skin firmness. Preferably the soy isoflavones are selected from genistein and daidzein.
It is also preferred that the product also comprises from 0.0005 to 0.1 wt% carotenoids. This is equivalent to from 0.5 to 100 mg/lOOg. Preferably the product contains from 0.002 to 0.04 wt% carotenoids. The carotenoids, being oil soluble, would be comprised predominantly within the oil phase. Highly preferred carotenoids are β-carotene, and lycopene. These carotenoids provide moderate protection from UV induced erythema, thought to be due to their antioxidant functionality including scavenging of reactive oxygen species.
Process for the manufacture of the product
The product of the present invention is made up by preparing an aqueous phase and an oil phase. In general the water-soluble ingredients are put together in the aqueous phase and the oil- soluble ingredients in the oil phase. The exception is the emulsifier. It has been surprisingly found that the emulsifier, which is oil-soluble, gives a more stable emulsion when it is added to the aqueous phase.
The two phases are then blended together in conventional emulsifier equipment. The produced emulsion is shelf-stable and the oil does not go rancid for months.
The oil phase and aqueous phase are then blended together to 'form a homogenous stable emulsion.
In a preferred process the oil is on a powdered carrier material to assist emulsion formation.
The stable emulsion may then be packaged in a sealed container such as a metal, coated cardboard (e.g. tetra Pak) or plastic container. The container is then preferably sealed so as to give no headspace or a gas filled (e.g. nitrogen or carbon dioxide) headspace. This assists still further in preventing the fish oil oxidising.
Alternatively the emulsion may be frozen and packaged and sold as a frozen consumer product.
EXAMPLES
Example 1
A beverage was made up with the following formula:
Figure imgf000009_0001
Figure imgf000010_0001
The beverage had a good taste and colour, and 150ml twice per day for a few weeks gave noticeable improvements in the appearance and texture of the skin.

Claims

1. A stable consumable emulsion, comprising at least 50% water, 0.2 to 5 wt% of an oil comprising at least 12wt% of docosahexaenoic acid and eicosapentaenoic acid, an antioxidant, a flavouring and at least 0.01 wt% food-grade phospholipid emulsifier.
2. A product according to any preceding claim, which also comprises from 0.0005 to 0.1 wt% carotenoid material.
3. A product according to any preceding claim, which also comprises from 0.01 to 0.5 wt% soy isoflavone material.
4. A product according to any preceding claim, wherein the flavouring comprises fruit and/or vegetable extract.
5. A product according to claim 3, wherein the soy isoflavone is selected from genistein and daidzein.
6. A product according to any preceding claim, wherein the phospholipid emulsifier is lecithin.
7. A product according to any preceding claim, which has a viscosity of from 2 to 100 centipoise at a shear rate of
Is'1 and at 25°C.
8. A product according to any preceding claim, wherein at least one component is naturally sourced, preferably the oil.
9. A product according to any preceding claim, which is a beverage packaged in a sealed container, the container having a nitrogen gas headspace.
10. A process for making a product according to any preceding claim, wherein an aqueous phase comprising the emulsifier and an oil phase comprising the fish oil are blended together to create a stable emulsion
PCT/EP2005/011658 2004-11-29 2005-10-28 Oral composition for enhancing skin properties Ceased WO2006056293A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
DE602005019207T DE602005019207D1 (en) 2004-11-29 2005-10-28 ORAL COMPOSITION TO IMPROVE SKIN PROPERTIES
AT05800022T ATE456373T1 (en) 2004-11-29 2005-10-28 ORAL COMPOSITION FOR IMPROVING SKIN PROPERTIES
EP05800022A EP1833498B1 (en) 2004-11-29 2005-10-28 Oral composition for enhancing skin properties
PL05800022T PL1833498T3 (en) 2004-11-29 2005-10-28 Oral composition for enhancing skin properties
US11/791,783 US20080200546A1 (en) 2004-11-29 2005-10-28 Oral Composition For Enhancing Skin Properties
US12/640,124 US20100093844A1 (en) 2004-11-29 2009-12-17 Oral composition for enhancing skin properties

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04257376.6 2004-11-29
EP04257376 2004-11-29

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/640,124 Continuation US20100093844A1 (en) 2004-11-29 2009-12-17 Oral composition for enhancing skin properties

Publications (1)

Publication Number Publication Date
WO2006056293A1 true WO2006056293A1 (en) 2006-06-01

Family

ID=34930850

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/011658 Ceased WO2006056293A1 (en) 2004-11-29 2005-10-28 Oral composition for enhancing skin properties

Country Status (8)

Country Link
US (2) US20080200546A1 (en)
EP (1) EP1833498B1 (en)
AT (1) ATE456373T1 (en)
DE (1) DE602005019207D1 (en)
ES (1) ES2337276T3 (en)
PL (1) PL1833498T3 (en)
RU (1) RU2396073C2 (en)
WO (1) WO2006056293A1 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007116052A1 (en) * 2006-04-12 2007-10-18 Unilever Plc Oral composition comprising dha and genistein for enhancing skin properties
WO2007115934A1 (en) * 2006-04-12 2007-10-18 Unilever Plc Oral composition with an antiageing effect on the skin
EP1897530A1 (en) * 2006-09-08 2008-03-12 DSMIP Assets B.V. Skin care composition
EP1911358A1 (en) * 2006-10-13 2008-04-16 Compagnie Gervais Danone New composition for improving skin quality and a process for preparing the same
EP1952796A1 (en) * 2006-09-08 2008-08-06 DSMIP Assets B.V. Skin care compositions
WO2009115769A1 (en) * 2008-03-18 2009-09-24 Robert Peter Taylor Composition for hair, skin and nail health maintenance
WO2010066641A1 (en) * 2008-12-11 2010-06-17 Unilever Plc Oral composition
EP2337834A4 (en) * 2008-09-19 2011-11-23 Epax As ANTIOXIDANT COMPOSITION FOR MARINE OILS COMPRISING TOCOPHEROL, ROSEMARY EXTRACT, ASCORBIC ACID AND GREEN TEA EXTRACT
RU2440117C1 (en) * 2007-10-05 2012-01-20 Торэй Индастриз, Инк. Therapeutic agent for improvement of skin properties containing morphinan derivative or any of its pharmacologically acceptable acid-additive salts as active ingredient
EP2004169B1 (en) * 2006-04-12 2012-08-08 Unilever PLC Oral composition comprising a polyunsaturated fatty acid and salicylic acid for obtaining an antiinflammatory effect in skin
CN102639015A (en) * 2009-09-04 2012-08-15 帝斯曼知识产权资产管理有限公司 Juice or nectar formulations

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8722131B2 (en) 2010-09-07 2014-05-13 Dsm Nutritional Products Ag Comestible emulsions
CN106176481A (en) * 2016-08-30 2016-12-07 广州品赫生物科技有限公司 A kind of edible cosmetic composition and preparation method thereof
KR20190111818A (en) 2018-03-23 2019-10-02 주식회사 오스테온 A composition having improved bioavailability of isoflavone

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4020874A1 (en) * 1989-06-29 1991-01-24 Niva Dr Shapira Soft drink giving protection against sun-light exposure - contains carotenoid and Vitamin=C or Vitamin=E
US5965153A (en) * 1998-03-24 1999-10-12 Stabar Enterprises, Inc. Dietary supplement for preventing or reducing shedding by animals
WO2001078674A1 (en) * 2000-04-18 2001-10-25 Ceteris Holding B.V. -Amsterdam (Olanda)- Succursale Di Lugano A composition based on natural extracts useful in the prevention and treatment of cutaneous wrinkles
US20030082275A1 (en) * 1999-12-28 2003-05-01 Johan Myhre Drinkable omega-3 preparation and storage stabilization
WO2004068970A2 (en) * 2003-01-31 2004-08-19 The Procter & Gamble Company Means for improving the appearance of mammalian keratinous tissue

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4347695A (en) * 1980-03-26 1982-09-07 General Foods Corporation Beverage bottling method
US4843095A (en) * 1987-08-07 1989-06-27 Century Laboratories, Inc. Free fatty acids for treatment or propyhlaxis of rheumatoid arthritis arthritis
US4963380A (en) * 1987-11-30 1990-10-16 General Mills, Inc. Beverages containing fish oils stabilized with fructose
US5290605A (en) * 1989-06-29 1994-03-01 Niva Shapira Sun-exposure nutritional supporting composition
RU2142830C1 (en) * 1997-09-24 1999-12-20 Институт биологии моря ДВО РАН Psoriasis treatment method
US6194379B1 (en) * 1998-05-01 2001-02-27 Abbott Laboratories Elemental enteral formula
FR2804023B1 (en) * 2000-01-26 2002-09-20 Johnson & Johnson Consumer Fr NUTRITIONAL SUPPLEMENT BASED ON CASSIS OIL
US20020188024A1 (en) * 2000-08-23 2002-12-12 Chilton Floyd H. Fatty acid-containing emulsion with increased bioavailability
JP2004515508A (en) * 2000-12-16 2004-05-27 アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング COMPOUND HEALTH PROMOTING COMPOSITION
US20040102421A1 (en) * 2002-11-21 2004-05-27 Children's Hospital Research Center At Oakland Tocopherol and tocotrienol anti-inflammatory medicaments

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4020874A1 (en) * 1989-06-29 1991-01-24 Niva Dr Shapira Soft drink giving protection against sun-light exposure - contains carotenoid and Vitamin=C or Vitamin=E
US5965153A (en) * 1998-03-24 1999-10-12 Stabar Enterprises, Inc. Dietary supplement for preventing or reducing shedding by animals
US20030082275A1 (en) * 1999-12-28 2003-05-01 Johan Myhre Drinkable omega-3 preparation and storage stabilization
WO2001078674A1 (en) * 2000-04-18 2001-10-25 Ceteris Holding B.V. -Amsterdam (Olanda)- Succursale Di Lugano A composition based on natural extracts useful in the prevention and treatment of cutaneous wrinkles
WO2004068970A2 (en) * 2003-01-31 2004-08-19 The Procter & Gamble Company Means for improving the appearance of mammalian keratinous tissue

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007116052A1 (en) * 2006-04-12 2007-10-18 Unilever Plc Oral composition comprising dha and genistein for enhancing skin properties
WO2007115934A1 (en) * 2006-04-12 2007-10-18 Unilever Plc Oral composition with an antiageing effect on the skin
US8987329B2 (en) 2006-04-12 2015-03-24 Conopco, Inc. Oral composition comprising a polyunsaturated fatty acid and salicylic acid for obtaining an antiinflammatory effect in skin
EP2004169B1 (en) * 2006-04-12 2012-08-08 Unilever PLC Oral composition comprising a polyunsaturated fatty acid and salicylic acid for obtaining an antiinflammatory effect in skin
EP2189155A1 (en) * 2006-04-12 2010-05-26 Unilever Plc, A Company Registered In England And Wales under company no. 41424 of Unilever House Oral composition with an antiaging effect on the skin
WO2008028636A1 (en) * 2006-09-08 2008-03-13 Dsm Ip Assets B.V. Skin care composition
WO2008028634A1 (en) * 2006-09-08 2008-03-13 Dsm Ip Assets B.V. Skin care composition
EP1897530A1 (en) * 2006-09-08 2008-03-12 DSMIP Assets B.V. Skin care composition
WO2008028632A1 (en) * 2006-09-08 2008-03-13 Dsm Ip Assets B.V. Skin care composition
WO2008028631A3 (en) * 2006-09-08 2008-06-05 Dsm Ip Assets Bv Skin care composition
EP1952796A1 (en) * 2006-09-08 2008-08-06 DSMIP Assets B.V. Skin care compositions
WO2008028633A1 (en) * 2006-09-08 2008-03-13 Dsm Ip Assets B.V. Skin care composition
JP2010502662A (en) * 2006-09-08 2010-01-28 ディーエスエム アイピー アセッツ ビー．ブイ． Skin care composition
WO2008043856A1 (en) * 2006-10-13 2008-04-17 Compagnie Gervais Danone New composition for improving skin quality and a process for preparing the same
EP1911358A1 (en) * 2006-10-13 2008-04-16 Compagnie Gervais Danone New composition for improving skin quality and a process for preparing the same
RU2440117C1 (en) * 2007-10-05 2012-01-20 Торэй Индастриз, Инк. Therapeutic agent for improvement of skin properties containing morphinan derivative or any of its pharmacologically acceptable acid-additive salts as active ingredient
WO2009115769A1 (en) * 2008-03-18 2009-09-24 Robert Peter Taylor Composition for hair, skin and nail health maintenance
EP2337834A4 (en) * 2008-09-19 2011-11-23 Epax As ANTIOXIDANT COMPOSITION FOR MARINE OILS COMPRISING TOCOPHEROL, ROSEMARY EXTRACT, ASCORBIC ACID AND GREEN TEA EXTRACT
US9301536B2 (en) 2008-09-19 2016-04-05 Epax Norway As Antioxidant composition for marine oils comprising tocopherol, rosemary extract, ascorbic acid and green tea extract
WO2010066641A1 (en) * 2008-12-11 2010-06-17 Unilever Plc Oral composition
CN102245177A (en) * 2008-12-11 2011-11-16 荷兰联合利华有限公司 Oral composition
US8546445B2 (en) 2008-12-11 2013-10-01 Conopco, Inc. Oral composition
CN102245177B (en) * 2008-12-11 2014-05-07 荷兰联合利华有限公司 Oral composition
CN102639015A (en) * 2009-09-04 2012-08-15 帝斯曼知识产权资产管理有限公司 Juice or nectar formulations

Also Published As

Publication number Publication date
RU2396073C2 (en) 2010-08-10
ATE456373T1 (en) 2010-02-15
ES2337276T3 (en) 2010-04-22
RU2007124378A (en) 2009-01-10
EP1833498B1 (en) 2010-01-27
EP1833498A1 (en) 2007-09-19
PL1833498T3 (en) 2010-06-30
DE602005019207D1 (en) 2010-03-18
US20100093844A1 (en) 2010-04-15
US20080200546A1 (en) 2008-08-21

Similar Documents

Publication Publication Date Title
US20100093844A1 (en) Oral composition for enhancing skin properties
US7041324B2 (en) Drinkable omega-3 preparation and storage stabilization
Walker et al. Improvements in the formation and stability of fish oil-in-water nanoemulsions using carrier oils: MCT, thyme oil, & lemon oil
Walker et al. Development of food-grade nanoemulsions and emulsions for delivery of omega-3 fatty acids: Opportunities and obstacles in the food industry
CA2694054C (en) Omega-3 fatty acid fortified composition
EP2189155B1 (en) Oral composition with an antiageing effect on the skin
US20140106047A1 (en) Prepared foods having high efficacy omega-6/omega-3 balanced polyunsaturated fatty acids
CA2857372C (en) Prepared foods having high efficacy omega-6/omega-3 balanced polyunsaturated fatty acids
US20110236560A1 (en) Food supplementation with phenolic antioxidants in vinegar
EP2285242B1 (en) Plant extract and pufa combinations
GB2217173A (en) Nutritional and medicinal compositions
JP6450317B2 (en) Soft capsule containing DHA and EPA
CN110692743A (en) Non-fishy stable non-polar component emulsion composition
JP2009225724A (en) Composition containing arachidonic acid
EP2398449B1 (en) Edible composition for treating cutaneous signs of ageing
CA2293088A1 (en) Method and composition for masking taste and odor from fish oil
CHARTERIS Minor ingredients of edible table spreads
HK1049947B (en) Drinkable omega-3 preparation
HK1226633A1 (en) Soft capsule containing dha and epa

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2005800022

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2007124378

Country of ref document: RU

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005800022

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11791783

Country of ref document: US